Fri, Aug 29, 2014, 3:58 PM EDT - U.S. Markets close in 2 mins.

Recent

% | $
Quotes you view appear here for quick access.

Corrections Corporation of America Message Board

Doctor_Of_Value 9 posts  |  Last Activity: Aug 17, 2014 7:56 PM Member since: Feb 19, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    OT

    by wall_street_titan Aug 16, 2014 12:21 PM
    doctor_of_value doctor_of_value Aug 17, 2014 7:56 PM Flag

    The short interest community has been very successful making money playing in the regenerative medicine space. While presumably legal, it has raised the cost of capital and slowed the development of legitimate stem cell therapies. No telling how much harm short sellers have inflicted upon mankind and the economies that pay for health care. That is a whole topic on its own!

    Cytori was not able to commercialize or leverage the data from European based Phase II data released in May of 2010. To angry investors it appears that all of the money raised by Cytori over the last 4 years was wasted purely on salaries with nothing to show for it. With the exception of Barda, this is largely true as all of the progress has been made by unaffiliated medical groups around the world who used the Celution System to obtain the cells for their research. As I see things today, Cytori looks to be the beneficiary of new Japanese stem cell regulation and a government sponsored Phase III trial on SUI. Remember the RESTORE I trial was conducted in Japan before RESTORE II went to Europe. The clinical trial in Spain for ACL repair and Scleroderma in France should lead to government sponsored Phase III trials. The data is now starting to come out from those 50+ clinical trials that we know nothing about. Okyanos and Lorem are examples of commercialization ventures creating demand for the stem cells. The future looks brighter than the past.

    I am not going to play the IF THIS HAPPENS, then the stock will go to $x game. For the speculative part of my portfolio, I am heavily invested in two stocks, one of which is CYTX.

    Sentiment: Strong Buy

  • Reply to

    OT

    by wall_street_titan Aug 16, 2014 12:21 PM
    doctor_of_value doctor_of_value Aug 17, 2014 7:28 PM Flag

    Yes, I am down about that much on paper and I continue to add shares from time to time. I have never sold a single share of Cytori, but I will admit the last 50,000 shares that I have purchased are designated to be trading shares. Over the last couple of years there have been a handful of biotech companies with similar balance sheets that have reported Phase II data from FDA approved trials. The first one was Pharmaset. They had 80MM shares outstanding, $10MM in annual revenue and a little more cash than Cytori has today. The results on their Hep C drug were strong and Gilead Scientific bought them out for $11 Billion in cash. The stock was trading at about $75 per share before the $140 buyout price. Just in the last month, there have been two other examples. I'm sure you can Google them.

    I do not understand why the investment community is willing to bid up companies like Pharmaset and completely ignore Cytori's potential. Cytori is not alone, all stem cell stocks are being ignored. The standard answer is that the investment community is not willing to place a large bet on a brand new industry before enough data is released and peer reviewed. I do not believe in a conspiracy theory that big pharma is influencing the FDA to slow the progress of stem cell therapies for as long as possible. Cytori is in possession of a letter to the FDA strongly asking that stem cells be considered drugs and that they should have to go through the same approval processes as the major drug companies. To treat stem cell companies differently would be giving them a development advantage over traditional pharmaceutical companies. This is not a conspiracy. It is a lobbying effort and is likely happening right now in Japan during the open period for public comment. (which I heard ended last Friday).

    Sentiment: Strong Buy

  • Reply to

    OT

    by wall_street_titan Aug 16, 2014 12:21 PM
    doctor_of_value doctor_of_value Aug 16, 2014 5:51 PM Flag

    One other thing, who is nobody?

  • Reply to

    OT

    by wall_street_titan Aug 16, 2014 12:21 PM
    doctor_of_value doctor_of_value Aug 16, 2014 5:49 PM Flag

    Look up my post from April 9th of this year. You must have missed that one.

  • Reply to

    OT

    by wall_street_titan Aug 16, 2014 12:21 PM
    doctor_of_value doctor_of_value Aug 16, 2014 4:17 PM Flag

    cytxer, what in the world are you talking about? I had no advance knowledge about the Athena trial being suspended and I have not posted since early June. I do not understand your banter or what you are trying to accomplish by making false statements about me.

  • Reply to

    doctor of value, are you still here?

    by devilsyankeesfan Jun 13, 2014 11:07 AM
    doctor_of_value doctor_of_value Jul 6, 2014 1:29 PM Flag

    I have not left. I own over 1% of the company and remain very bullish on the technology. I am somewhat disappointed at the slow pace of the CardioPet trial. I realize the Belgian hospital is not a big cardiac center and suitable candidates are slow to present themselves. Thijs Spoor has stated several times that this trial is very close to completion meaning to me we have one, two, or three more scans to complete. Trial results from CardioPet are crucial to gaining a partner to fund both CardioPet and BFPet Phase III trials. Because of the extra time it has taken to complete the CardioPet Phase II trial, it seems likely the company will need to raise additional funds on its own to conclude the BFPet Phase II trial.

    The BFPet trial should have already begun enrollment but has not. Last week's 8K filing explains that delay. We should hear news in July regarding the first patient being scanned and as I understand it, this trial should move rapidly because there is no shortage of qualified candidates. All in all, I would say we are about three months behind plan regarding the trials, but we are light years ahead in building a management team, a scientific advisory board and Board of Directors. This part of the equation is really quite remarkable. Still a risky investment, but the probability of success is increasing rapidly.

    Sentiment: Strong Buy

  • doctor_of_value doctor_of_value Jun 13, 2014 8:09 AM Flag

    WST, it doesn't make a lot of sense to me either. Calhoun is looking for a new job to support his life style. Perhaps something was already far enough down the road to just let Calhoun handle it so everyone else could focus on Barda. Just to be clear, I have no opinion on the rumor and don't really believe it. I only mentioned it because Saad correctly would not comment on the rumor. Wish I could recall the sentence but I can't.

  • doctor_of_value doctor_of_value Jun 13, 2014 8:03 AM Flag

    No offense taken. Saad never tells me anything in confidence. That would violate the SEC rules and he is very careful about that. I probably should have not mentioned a rumor that I don't really believe. As far as my last sentence, permit me to clarify. I am referring to all of the small clinical trials conducted by doctors around the world where the Celution system has been the source of the cells. Cytori does not own the data and in many cases is not made privvy to the trial results. Many of us have expressed frustration and some have accused Cytori of withholding clinical data from the stockholders. These trials are generating data, which is progress. My comment was to express my frustration over the lack of knowledge about these trials. Regenerative medicine has a long way to go before it becomes recognized as "the next big thing." Strong US based clinical data is the key. Success with Barda is a statement from the US government that the technology works. Clinical data from Athena is a statement from the medical world that the technology works.

  • doctor_of_value doctor_of_value Jun 12, 2014 7:02 PM Flag

    Good post, hearnelaura! I was in San Diego last night and met Mark Saad after work. He was very clear saying that Barda had reviewed and approved the shareholder letter that was posted on the website. In fact, it was Barda who changed the wording to: "During the initial base period of the contract, three targeted milestones were completed, potentially allowing Barda to expand the contract award beyond the base period funding," Again, that sentence was added by Barda. While the odds a ridiculously low, it is still possible the panel could deviate from the expected decision. If I remember correctly, there were six different government agencies in the room and all were highly interested in the project.

    Because the outcome of the IPR meeting was unknown, David Rickey was legally able to buy stock on the previous Friday. Saad is looking to use the ATM at prices above $3. A number of large institutional money managers consider a Barda contract beyond the initial base period provides enough justification to buy the stock. In the coming quarters, we should see new names as owners.

    I had heard some rumors that Chris Calhoun was in the UK and still working on a deal. When I asked Saad about that, he clammed up tight and moved away from the question. Not sure how to read that. Calhoun does have a track record of completing small deals, but letting the big ones get away. There is good work being done in Spain in the area of ACL healing. We will see.

    My first purchase was June 22, 2010. All of the progress that has been made over the last four years is behind the scenes and unknown to us. It is about time Cytori actually achieves something of significance.

    Sentiment: Strong Buy

CXW
35.67+0.080(+0.22%)3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.